Clinical Drug Investigation

, Volume 32, Issue 2, pp 73–85 | Cite as

Implementing an Influenza Vaccination Programme for Adults Aged ≥ 65 Years in Poland

A Cost-Effectiveness Analysis
  • Lidia Brydak
  • Julie Roiz
  • Pascaline Faivre
  • Camille Reygrobellet
Original Research Article


Background and Objectives: Influenza is a common respiratory disease occurring in seasonal patterns, and may lead to severe complications in frail populations such as the elderly. In Poland, influenza vaccination is recommended for people aged ≥65 years; however the vaccine coverage rate in the elderly is very low. The fact that influenza vaccine is neither reimbursed by the National Health Insurance (Narodowy Fundusz Zdrowia [NFZ]) nor financed via a National Immunization Program (NIP) could be a reason for the low coverage rate. This study assessed the cost effectiveness of the full reimbursement of an influenza vaccination programme in Poland for people aged ≥65 years.

Methods: A decision-analytic model was developed to compare costs and outcomes associated with the current situation in which influenza vaccination is not reimbursed and a new situation in which it would be fully covered by the NFZ. The model was parameterized to Poland using data from the literature and from the Central Statistic Office of Poland. Within the elderly population, 50% were considered to be at high risk of influenza complications. An influenza attack rate of 3.5% was used for calculation purposes. Influenza-associated hospitalizations and death rates were estimated at 439.9 per 100 000 person-years and 79.1 per 100 000 person-years, respectively. Cost estimates were derived from a cost study conducted in Poland. Costs are presented in Polish Zloty (PLN) [2009 mean exchange rate: 1 PLN= €0.232]. Only direct medical costs were included to fit to the NFZ perspective. To reflect the seasonality of influenza, a time horizon of 1 year was chosen. Life-years and quality-adjusted life-years (QALYs) accumulated over future years were discounted at a rate of 5% as recommended by Polish guidelines. Deterministic and probabilistic sensitivity analyses were conducted.

Results: In Poland, the introduction of the public funding of influenza vaccination for people aged ≥65 years would cost PLN 79 million when an increase in coverage rate from 13.5% to 40% is assumed. 23 900 cases of influenza, 1777 hospitalizations and 548 premature deaths would be averted each year due to the influenza vaccination programme. Fifty-seven persons would need to be vaccinated to prevent one case of influenza. To prevent one hospitalization and one death due to influenza, 842 and 2809 individuals would need to be vaccinated, respectively. The new strategy would be very cost effective compared with the current situation with an incremental cost-effectiveness ratio (ICER) of PLN26 118/QALY, which is below the 2009 yearly gross domestic product (GDP) per capita. Deterministic sensitivity analyses demonstrated that the most influential variables for the ICER were vaccine efficacy against death, excess hospitalization rate, utility norms, influenza attack rate, vaccine efficacy against hospitalization, and discount rates. All ICERs computed were below the threshold of 3 GDP per capita. From the probabilistic analysis, the proposed new influenza vaccination programme, if implemented, was predicted to be cost effective from the NFZ perspective with a probability of 100%, given the same threshold.

Conclusion: Implementing a vaccination programme in Poland in which influenza vaccination would be fully reimbursed by the NFZ for people aged ≥65 years would be a very cost-effective strategy.


  1. 1.
    Plotkin SA, Orenstein WA, Offit PA. Inactivated Influenza vaccine. Vaccine. 5 ed. Philadelphis (PA): Saunders Elsevier 2011; 260Google Scholar
  2. 2.
    de Lataillade C, Auvergne S, Delannoy I. 2005 and 2006 seasonal influenza vaccination coverage rates in 10 countries in Africa, Asia Pacific, Europe, Latin America and the Middle East. J Public Health Policy 2009 Apr; 30(1): 83–101PubMedCrossRefGoogle Scholar
  3. 3.
    Brydak LB. Influenza: flu pandemic, myth or a real threat [in Polish]? Wyd Rytm Warszawa 2008; 1–492Google Scholar
  4. 4.
    Kardas P, Zasowska A, Dec J, et al. Reasons for low influenza vaccination coverage: cross-sectional survey in Poland. Croat Med J 2011 April; 52(2): 126–33PubMedCrossRefGoogle Scholar
  5. 5.
    Blank PR, Schwenkglenks M, Szucs TD. Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons. Infection 2009; 37: 390–400PubMedCrossRefGoogle Scholar
  6. 6.
    Allsup S, Gosney M, Haycox A, et al. Cost-benefit evaluation of routine influenza immunisation in people 65–74 years of age. Health Technol Assess 2003; 7(24): iii–65PubMedGoogle Scholar
  7. 7.
    Allsup SH. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine 2004; 23: 639–45PubMedGoogle Scholar
  8. 8.
    Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002 Jun 7; 20(19–20): 2562–78PubMedCrossRefGoogle Scholar
  9. 9.
    Mullooly JP, Bridges CB, Thompson WW, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007 Jan 15; 25(5): 846–55PubMedCrossRefGoogle Scholar
  10. 10.
    Kroneman M, van Essen GA, John PW. Influenza vaccination coverage and reasons to refrain among high-risk persons in four European countries. Vaccine 2006 Jan 30; 24(5): 622–8PubMedCrossRefGoogle Scholar
  11. 11.
    Nitsch-Osuch A, Wardyn K, Choroszi-Krol I. Pneumococcal and influenza vaccine coverage in persons aged above 65 years in 2004–2006 in Poland. Slides presented at the ESWI conference, Poland: 2008Google Scholar
  12. 12.
    Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006; 3: CD004876PubMedGoogle Scholar
  13. 13.
    Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994 Dec 7; 272(21): 1661–5PubMedCrossRefGoogle Scholar
  14. 14.
    Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007 Oct 4; 357(14): 1373–81PubMedCrossRefGoogle Scholar
  15. 15.
    [No authors listed]. Influenzapandemieplanung: Nationaler Influenzapandemieplan. Bundesgesundheitsblatt — Gesundheitsforschung — Gesundheitsschutz 2005;48:356-390Google Scholar
  16. 16.
    Cartter ML, Renzullo PO, Helgerson SD, et al. Influenza outbreaks in nursing homes: how effective is influenza vaccine in the institutionalized elderly? Infect Control Hosp Epidemiol 1990 Sep; 11(9): 473–8PubMedCrossRefGoogle Scholar
  17. 17.
    Deguchi Y, Takasugi Y, Nishimura K. Vaccine effectiveness for influenza in the elderly in welfare nursing homes during an influenza A (H3N2) epidemic. Epidemiol Infect 2000 Oct; 125(2): 393–7PubMedCrossRefGoogle Scholar
  18. 18.
    Edmondson Jr WP, Rothenberg R, White PW, et al. A comparison of subcutaneous, nasal, and combined influenza vaccination: II. Protection against natural challenge. Am J Epidemiol 1971 Jun; 93(6): 480–6PubMedGoogle Scholar
  19. 19.
    Gorse GJ, O’Connor TZ, Young SL, et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003 May 16; 21(17–18): 2133–44PubMedCrossRefGoogle Scholar
  20. 20.
    Gravenstein S, Drinka P, Duthie EH, et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 1994 Mar; 42(3): 245–51PubMedGoogle Scholar
  21. 21.
    Gross PA, Rodstein M, LaMontagne JR, et al. Epidemiology of acute respiratory illness during an influenza outbreak in a nursing home: a prospective study. Arch Intern Med 1988 Mar; 148(3): 559–61PubMedCrossRefGoogle Scholar
  22. 22.
    Hara M, Sakamoto T, Tanaka K. Effectiveness of influenza vaccination in preventing influenza-like illness among community-dwelling elderly: population-based cohort study in Japan. Vaccine 2006; 24: 5546–51PubMedCrossRefGoogle Scholar
  23. 23.
    Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006 Dec 16; 333(7581): 1241PubMedCrossRefGoogle Scholar
  24. 24.
    Howarth DM, Chaston TM, Lickiss K, et al. Age-related responses to influenza vaccination in the Newcastle region during 1983 and 1984. Med J Aust 1987 May 18; 146(10): 514–7PubMedGoogle Scholar
  25. 25.
    Kawai N, Ikematsu H, Iwaki N, et al. A prospective, internet-based study of the effectiveness and safety of influenza vaccination in the 2001–2002 influenza season. Vaccine 2003 Nov 7; 21(31): 4507–13PubMedCrossRefGoogle Scholar
  26. 26.
    Mangtani P, Cumberland P, Hodgson CR, et al. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004 Jul 1; 190(1): 1–10PubMedCrossRefGoogle Scholar
  27. 27.
    Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001 Jul 15; 154(2): 155–60PubMedCrossRefGoogle Scholar
  28. 28.
    Morens DM, Rash VM. Lessons from a nursing home outbreak of influenza A. Infect Control Hosp Epidemiol 1995 May; 16(5): 275–80PubMedCrossRefGoogle Scholar
  29. 29.
    Murasko DM, Bernstein ED, Gardner EM, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002 Jan; 37(2–3): 427–39PubMedCrossRefGoogle Scholar
  30. 30.
    Murayama N, Suzuki H, Arakawa M, et al. Two outbreaks of influenza A (H3N2) in a Japanese nursing home in the winter of 1996–1997, with differing vaccine efficacy. Tohoku J Exp Med 1999 Aug; 188(4): 289–98PubMedCrossRefGoogle Scholar
  31. 31.
    Nichol KL, Margolis KL, Wuorenma J,et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994 Sep 22; 331(12): 778–84PubMedCrossRefGoogle Scholar
  32. 32.
    Nichol KL, Wuorenma J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998 Sep 14; 158(16): 1769–76PubMedCrossRefGoogle Scholar
  33. 33.
    Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003 May 16; 21(17–18): 2216–26Google Scholar
  34. 34.
    Nicholson KG, Kent J, Hammersley V. Influenza A among community-dwelling elderly persons in Leicestershire during winter 1993–4; cigarette smoking as a risk factor and the efficacy of influenza vaccination. Epidemiol Infect 1999 Aug; 123(1): 103–8PubMedCrossRefGoogle Scholar
  35. 35.
    Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005 Feb 18; 23(13): 1540–8PubMedCrossRefGoogle Scholar
  36. 36.
    Ruben FL. Effectiveness of current killed influenza vaccines against influenza A-England-42-72. J Infect Dis 1973 May; 127(5): 576–7PubMedCrossRefGoogle Scholar
  37. 37.
    Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993 Oct; 168(4): 881–7PubMedCrossRefGoogle Scholar
  38. 38.
    Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000 Sep 15; 19(2–3): 308–18PubMedCrossRefGoogle Scholar
  39. 39.
    Saito R, Suzuki H, Oshitani H, et al. The effectiveness of influenza vaccine against influenza a (H3N2) virus infections in nursing homes in Niigata, Japan, during the 1998–1999 and 1999–2000 seasons. Infect Control Hosp Epidemiol 2002 Feb; 23(2): 82–6PubMedCrossRefGoogle Scholar
  40. 40.
    Stuart WH, Dull HB, Newton LH, et al. Evaluation of monovalent influenza vaccine in a retirement community during the epidemic of 1965–66. JAMA 1969 Jul 14; 209(2): 232–8PubMedCrossRefGoogle Scholar
  41. 41.
    Taylor JL, Dwyer DM, Coffman T, et al. Nursing home outbreak of influenza A (H3N2): evaluation of vaccine efficacy and influenza case definitions. Infect Control Hosp Epidemiol 1992 Feb; 13(2): 93–7PubMedCrossRefGoogle Scholar
  42. 42.
    Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004 Sep 15; 292(11): 1333–40PubMedCrossRefGoogle Scholar
  43. 43.
    Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 Jan 8; 289(2): 179–86PubMedCrossRefGoogle Scholar
  44. 44.
    Szende A, Nemeth R. Health-related quality of life of the Hungarian population. Orv Hetil 2003 Aug 24; 144(34): 1667–74PubMedGoogle Scholar
  45. 45.
    British health Survey. Table 5.29: mean EuroQol tariff, by age and sex [online]. Available from URL: [Accessed 2011 May 11]
  46. 46.
    Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005 Jan; 118(1): 68–77PubMedCrossRefGoogle Scholar
  47. 47.
    Polish pharmacoeconomic society website. 2011 [online]. Available from URL: 2011/informacje [Accesssed 2011 Oct 1]
  48. 48.
    US Census Bureau International Database. Population Poland 2009 [online]. Available from URL: [Accessed 2009 Sep 9]
  49. 49.
    Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000 Nov; 19(11): 834–42PubMedCrossRefGoogle Scholar
  50. 50.
    Irwin DE, Weatherby LB, Huang WY, et al. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res 2001; 1(1): 8PubMedCrossRefGoogle Scholar
  51. 51.
    Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics 2001; 19(3): 293–301PubMedCrossRefGoogle Scholar
  52. 52.
    Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002 Aug 15; 35(4): 370–7PubMedCrossRefGoogle Scholar
  53. 53.
    Gerbier S, Barret B. Assessment of influenza vaccine efficacy/effectiveness in the elderly: Sanofi Pasteur internal report [data on file]. 2007Google Scholar
  54. 54.
    Voordouw BC, van der Linden PD, Simonian S, et al. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. Arch Intern Med 2003 May 12; 163(9): 1089–94PubMedCrossRefGoogle Scholar
  55. 55.
    Schanzer DL, Langley JM, Tam TW. Co-morbidities associated with influenza-attributed mortality, 1994–2000, Canada 14. Vaccine 2008; 26(36): 4697–703PubMedCrossRefGoogle Scholar
  56. 56.
    de Andres AL, Garrido PC, Hernandez-Barrera V, et al. Influenza vaccination among the elderly Spanish population: trend from 1993 to 2003 and vaccination-related factors. Eur J Public Health 2007 Jun; 17(3): 272–7PubMedCrossRefGoogle Scholar
  57. 57.
    Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995 Oct 1; 123(7): 518–27PubMedGoogle Scholar
  58. 58.
    Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007 Apr 12; 25(15): 2842–51PubMedCrossRefGoogle Scholar
  59. 59.
    Mazick A, Christiansen AH, Samuelsson S, et al. Using sentinel surveillance to monitor effectiveness of influenza vaccine is feasible: a pilot study in Denmark. Euro Surveill 2006; 11(10): 254–6PubMedGoogle Scholar
  60. 60.
    Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. J Infect Dis 2009 Jan 15; 199(2): 159–67PubMedCrossRefGoogle Scholar
  61. 61.
    Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; (2): CD001269Google Scholar
  62. 62.
    Vu T, Farish S, Jenkins M, et al. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002 Mar 15; 20(13–14): 1831–6PubMedCrossRefGoogle Scholar
  63. 63.
    Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007 Oct; 7(10): 658–66PubMedCrossRefGoogle Scholar
  64. 64.
    Ortqvist A, Granath F, Askling J, et al. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. Eur Respir J 2007 Sep; 30(3): 414–22PubMedCrossRefGoogle Scholar
  65. 65.
    Groenwold RH, Hoes AW, Hak E. Impact of influenza vaccination on mortality risk among the elderly. Eur Respir J 2009 Jul; 34(1): 56–62PubMedCrossRefGoogle Scholar
  66. 66.
    Szende A, Williams A. Measuring self-reported population health: an international perspective based on EQ-5D. EuroQoL group Monographs volume 1. Budapest: SpringMed Publishing; 2004Google Scholar
  67. 67.
    Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults. J Gen Intern Med 2003 Oct; 18(10): 808–15PubMedCrossRefGoogle Scholar
  68. 68.
    Rothberg MB, Fisher D, Kelly B, et al. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy. Arch Pediatr Adolesc Med 2005 Nov; 159(11): 1055–62CrossRefGoogle Scholar
  69. 69.
    Jahnz-Rozyk K. Health economic impact of viral respiratory infections and pneumonia diseases on the elderly population in Poland. Merkuriusz Lekarski 2010; 169: 37–40Google Scholar
  70. 70.
    Jahnz-Rozyk K. Pharmaco-economics of anti-influenza vaccinations. Pol Merkur Lekarski 2003 Jun; 14(84): 679–81PubMedGoogle Scholar
  71. 71.
    Central statistical office. Concise statistical yearbook of Poland-Maly Rocznik Statystyczny polski. 2010 [online]. Available from URL: [Accessed 2009 Aug 28]
  72. 72.
    Newall AT, Kelly H, Harsley S, et al. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. Pharmacoeconomics 2009; 27(6): 439–50PubMedCrossRefGoogle Scholar
  73. 73.
    Nielen MMJ, Spreeuwenberg P, Paget WJ, et al. The age-specific impact of influenza on hospital admissions and mortality in five countries in Europe. Utrecht: NIVEL; 2010Google Scholar
  74. 74.
    Pradas-Velasco R, Antonanzas-Villar F, Martinez-Zarate MP. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination. Pharmacoeconomics 2008; 26(1): 45–56PubMedCrossRefGoogle Scholar
  75. 75.
    Kwong JC, Stukel TA, Lim J, et al. The effect of universal influenza immunization on mortality and health care use 1. PLoS Med 2008 Oct 28; 5(10): e211PubMedCrossRefGoogle Scholar
  76. 76.
    World Health Organisation. Guidelines of standardization of economic evaluations of immunization programmes. 2008 [online]. Available from URL: [Accessed 2011 Oct 1]

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Lidia Brydak
    • 1
  • Julie Roiz
    • 2
  • Pascaline Faivre
    • 2
  • Camille Reygrobellet
    • 3
  1. 1.Department of Influenza ResearchNational Institute of Public HealthWarsawPoland
  2. 2.OptumInsightNanterreFrance
  3. pasteurLyonFrance

Personalised recommendations